Collegeville, PA, United States of America

Robert Anthony Galemmo, Jr


Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2003-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Robert Anthony Galemmo, Jr.

Introduction

Robert Anthony Galemmo, Jr. is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of factor Xa inhibitors. With a total of 2 patents, his work has had a meaningful impact on medical research and drug development.

Latest Patents

Galemmo's latest patents include innovative compounds such as 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones, which are useful as factor Xa inhibitors. Additionally, he has developed N-(amidinophenyl)cyclourea analogs that also serve as factor Xa inhibitors. These inventions are crucial in the ongoing efforts to create effective anticoagulant therapies.

Career Highlights

Currently, Robert Anthony Galemmo, Jr. is employed at Bristol-Myers Squibb Pharma Company, where he continues to advance his research in the pharmaceutical industry. His work at this prestigious company allows him to collaborate with leading experts in the field and contribute to groundbreaking medical advancements.

Collaborations

Throughout his career, Galemmo has worked alongside talented colleagues, including Mimi Lifen Quan and Donald Joseph Philip Pinto. These collaborations have fostered an environment of innovation and creativity, leading to the successful development of new pharmaceutical solutions.

Conclusion

Robert Anthony Galemmo, Jr. exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations highlight the importance of research and development in creating effective medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…